Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

NCT02965378 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02965378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02965378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2014
Completion date
October 31, 2019
Enrollment
43 (actual)
Sites
1,084

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr1 gene amplification, fgfr1 gene mutation, fgfr2 gene amplification, fgfr2 gene mutation, fgfr3 gene amplification, fgfr3 gene mutation, recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7